Increasing Tysabri dosing interval may cut PML risk

A board to discuss the newly-released drug Tysabri, (formerly known as Antegren) as a treatment for Multiple Sclerosis
Post Reply
User avatar
MSUK
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 2:00 pm
Contact:

Increasing Tysabri dosing interval may cut PML risk

Post by MSUK »

Freedom from relapse was maintained in multiple sclerosis patients on Tysabri who received the infusion drug less frequently than the recommended 4-week interval, with lower risk of progressive multifocal leukoencephalopathy (PML), preliminary results from an ongoing analysis have indicated...... Read More - http://www.ms-uk.org/tysabri
MS-UK - http://www.ms-uk.org/
User avatar
NHE
Volunteer Moderator
Posts: 6221
Joined: Sat Nov 20, 2004 3:00 pm
Contact:

Re: Increasing Tysabri dosing interval may cut PML risk

Post by NHE »

Prior to any flag waving, please note that this is not a randomized double blind controlled trial...
Weinshenker commented that selection of patients for extended dosing, which was not random, might have involved "biases against committing more aggressive MS patients on the extended interval program, which might reduce the ability of the investigators to detect reduction in efficacy."
Post Reply
  • Similar Topics
    Replies
    Views
    Last post

Return to “Tysabri (Antegren, Natalizumab)”